NASA Spotlights Angiex’s Space-Based Cancer Research as a Healthcare Breakthrough
Angiex was featured in a NASA article showcasing how research on the International Space Station (ISS) is driving health innovations on Earth. Angiex’s novel cancer therapy, aimed at disrupting the blood supply to tumors, is undergoing testing in the ISS’s microgravity environment. This unique setting allows scientists to observe endothelial cell behavior in a dormant state, which could provide key insights into the therapy’s safety for healthy blood vessels.
The article highlights how NASA’s support for biotech research in space enables companies like Angiex to push the boundaries of oncology. By leveraging microgravity, Angiex hopes to gather critical data that could enhance the safety and effectiveness of its TM4SF1-targeted therapy for cancer patients. This collaboration with NASA marks an exciting leap forward in using space for groundbreaking health advancements.